Strengthen cellular analysis with cost-efficient multiomic readouts and streamlined workflows

通过具有成本效益的多组读数和简化的工作流程加强细胞分析

PLEASANTON, Calif., Sept. 14, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new kit to expand the capabilities of its Chromium Single Cell Gene Expression Flex assay to include high-throughput multiomic cellular profiling.

加利福尼亚州普莱森顿，2023年9月14日/PRNewswire/-10x Genomics，Inc。（纳斯达克股票代码：TXG），单细胞和空间生物学的领导者，今天宣布商业上提供一种新试剂盒，以扩大其能力。铬单细胞基因表达Flex测定包括高通量多组细胞分析。

The new kit enables streamlined, multiomic characterization of cell populations so that researchers can expand their options at a larger scale and detect simultaneous gene and protein expression..

新试剂盒可对细胞群进行简化的多组学表征，使研究人员能够更大规模地扩展其选择范围，同时检测基因和蛋白质的表达。。

'We're building on the momentum and enthusiasm for Chromium Flex by enabling researchers to gain more insights from a single experiment at scale,' said Ben Hindson, Co-founder and Chief Scientific Officer at 10x Genomics. 'With this latest launch, multiomic million-cell experiments are now accessible at a fraction of the cost.'.

“我们正在建立在Chromium Flex的势头和热情之上，使研究人员能够从大规模的单一实验中获得更多见解，”10x Genomics的联合创始人兼首席科学官Ben Hindson说随着这一最新推出，现在可以以一小部分成本获得数百万细胞实验。

The new Feature Barcode Multiplexing kit is part of the company's Chromium Single Cell Gene Expression Flex portfolio, which enables researchers to:

新功能条形码多路复用套件是该公司Chromium单细胞基因表达Flex产品组合的一部分，该产品组合使研究人员能够：

Fix and store samples without losing data quality, letting scientists run samples later and simplify transport

在不损失数据质量的情况下修复和存储样品，让科学家稍后运行样品并简化运输

Detect proteins at single cell resolution with workflows that enable small- to large-scale studies

使用能够进行小规模到大规模研究的工作流程以单细胞分辨率检测蛋白质

Batch and scale to profile up to 1M cells in a single run and save up to 75% on per-sample costs

批量和规模，一次运行可分析多达100万个电池，每个样品成本可节省高达75%

Bring scRNA-seq with industry-leading sensitivity to fresh, frozen or fixed tissue – even FFPE

将scRNA-seq与行业领先的敏感性新鲜，冷冻或固定组织-甚至FFPE

'Single cell technologies have been transformative for our understanding of human health and disease,' said Peter Skene, Director of High Resolution Translational Immunology at the Allen Institute. 'Historically, single cell multi-omics have only profiled 1000s of cells per experiment, limiting the depth and breadth of questions that can be answered.

艾伦研究所高分辨率转化免疫学主任彼得·斯肯（Peter Skene）说：“单细胞技术对于我们理解人类健康和疾病具有变革性。”从历史上看，单细胞多组学每个实验只能分析1000个细胞，限制了可以回答的问题的深度和广度。

New highly multiplexed single cell technologies, such as 10x Genomics Flex protein multiplex, allow the simultaneous measurement of RNA and protein from millions of cells at a significantly lower cost point. This is a game changer for the research community and will expand opportunities and impact for human health.'  .

新的高度多路复用的单细胞技术，如10x Genomics Flex protein multiplex，可以以更低的成本点同时测量来自数百万细胞的RNA和蛋白质。这对研究界来说是一个改变游戏规则的因素，将扩大对人类健康的机遇和影响 .

The new Feature Barcode Multiplexing Kit is now shipping.

新功能条形码多路复用套件现已上市。

About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology.

大约10x Genomics10x Genomics是一家生命科学技术公司，致力于加速生物学掌握和促进人类健康。我们的综合解决方案包括用于单细胞和空间生物学的仪器，消耗品和软件，这有助于学术和转化研究人员以及生物制药公司以与生物学复杂性相匹配的分辨率和规模理解生物系统。

Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter)..

我们的产品落后于肿瘤学，免疫学，神经科学等领域的突破，推动了正在改变世界对健康和疾病认识的强大发现。要了解更多信息，请访问10xgenomics.com或通过LinkedIn或X（Twitter）与我们联系。。

Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the 'safe harbor' created by those sections.

前瞻性声明本新闻稿包含1995年“私人证券诉讼改革法”含义内的前瞻性声明，该法案载于1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条，经修订，受这些部分创建的“安全港”的约束。

All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as 'may,' 'might,' 'will,''enable,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential,' 'would,' 'likely,' 'seek' or 'continue' or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking.

除历史事实陈述外，所有陈述都可能是前瞻性陈述。前瞻性陈述通常可以通过使用前瞻性术语来确定，例如“可能”，“可能”，“将会”，“能够”，“应该”，“期望”，“计划”，“预期”，“可以，“，”意图“，”目标“，”项目“，”考虑“，”相信“，”估计“，”预测“，”潜在“，”可能“，”寻求“或”继续“或这些术语或其变体或类似术语的否定，但是缺少这些词语并不意味着一个陈述不是前瞻性的。

These forward-looking statements include statements regarding 10x Genomics, Inc.'s expectations regarding the continued growth and expansion of our Chromium platform, its performance and our product momentum and progress. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors.

这些前瞻性声明包括关于10x Genomics，Inc。对我们的Chromium平台的持续增长和扩展，其性能以及我们的产品势头和进步的期望的声明。这些陈述基于管理层目前可用于管理层的预期，预测，信念，假设和信息，由于许多因素，实际结果和结果可能与这些陈述有很大差异。

The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation.

可能影响10x Genomics，Inc。财务和运营结果并导致实际结果与本新闻稿中前瞻性声明所表明的实质风险和不确定性包括标题“风险因素”下讨论的那些风险和不确定性。和'管理层对财务状况和运营结果的讨论和分析。

Although 10x Genomics, Inc. believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur.

尽管10x Genomics，Inc.认为前瞻性陈述中反映的期望是合理的，但它不能提供任何保证，证明这些期望将被证明是正确的，也不能保证未来的结果，活动水平，表现和事件以及前瞻性陈述中反映的情况将得到实现或发生。

These forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments 10x Genomics, Inc. may make. Further, such forward-looking statements may not accurately or fully reflect the potential impact of adverse geopolitical and macroeconomic events, product capabilities and adoption rates, international economic, political, legal, compliance, social and business factors, such as the COVID-19 pandemic, inflation, supply chain that may have on the business, financial condition, results of operations and cash flows of 10x Genomics, Inc.

这些前瞻性陈述并未反映未来任何收购，合并，处置，合资企业或投资10x Genomics，Inc.可能产生的潜在影响。此外，这些前瞻性陈述可能无法准确或充分反映不利地缘政治和宏观经济事件，产品能力和采用率，国际经济，政治，法律，合规性，社会和商业因素（如COVID-19大流行）的潜在影响。，通货膨胀，可能对业务，财务状况，10x Genomics，Inc.的运营和现金流量结果。

The forward-looking statements in this press release are based on information available to 10x Genomics, Inc. as of the date hereof, and 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law.

本新闻稿中的前瞻性声明基于截至本声明之日10x Genomics，Inc。可获得的信息，10x Genomics，Inc。不承担任何更新任何前瞻性声明的义务，以反映我们预期的任何变化或任何此类声明所依据的事件，条件或环境的任何变化，除非法律要求。

These forward-looking statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release..

截至本新闻稿发布之日起的任何日期，这些前瞻性陈述均不应被视为代表10x Genomics，Inc.的观点。。

Disclosure Information10x Genomics, Inc. uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD..

披露信息10X Genomics，Inc.使用与证券交易委员会，我们的网站（www.10xgenomics.com），新闻稿，公开电话会议，公共网络广播和我们的社交媒体帐户的文件作为披露材料非公开信息的手段，并遵守我们在FD法规下的披露义务。。

ContactsInvestors: [email protected] Media: [email protected]

联系人：[电子邮件保护]媒体：[电子邮件保护]

SOURCE 10x Genomics, Inc.

来源10x Genomics，Inc。